LIPO GANTRISIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lipo Gantrisin, and what generic alternatives are available?
Lipo Gantrisin is a drug marketed by Roche and is included in one NDA.
The generic ingredient in LIPO GANTRISIN is sulfisoxazole acetyl. There are three drug master file entries for this compound. Additional details are available on the sulfisoxazole acetyl profile page.
Summary for LIPO GANTRISIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Patent Applications: | 1,689 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LIPO GANTRISIN at DailyMed |
US Patents and Regulatory Information for LIPO GANTRISIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Roche | LIPO GANTRISIN | sulfisoxazole acetyl | EMULSION;ORAL | 009182-009 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |